Cytokinetics, Incorporated (CYTK)

NASDAQ

$62.15

-$1.20 (1.89%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$62.09$64.11

Open $63.40

52 Week Range

$29.31$69.33

Previous Close $63.35

Market Cap7.39B

Volume1.53M

Avg Volume2.02M

P/E (TTM)-9.92

EPS (TTM)$-6.27

Dividend / YieldN/A

Dividend StreakN/A

Latest News for Cytokinetics, Incorporated

DEC12

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee ...

globenewswire.com•3 days ago

DEC8

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Added 458,295 shares of Cytokinetics, a $25,187,893 net position change Transaction represents a 13.8% position relative to 13F reportable assets under management Post-trade stake: 458,295 shares valu...

fool.com•7 days ago

DEC8

Cytokinetics (NASDAQ:CYTK) EVP Sells $3,461,451.70 in Stock

Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) EVP Andrew Callos sold 52,486 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $...

defenseworld.net•8 days ago

DEC5

Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?...

zacks.com•10 days ago

NOV24

Cytokinetics, Incorporated $CYTK Shares Acquired by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) by 8.8% in the second quarter, according to its most recent Form ...

defenseworld.net•22 days ago

NOV19

Cytokinetics: A Heavily Mispriced Cardiovascular Platform

Cytokinetics is positioned as a precision cardiac mechanics platform leader, with aficamten as the first proof-of-concept and multiple pipeline assets. Aficamten's differentiated REMS, rapid titration...

seekingalpha.com•26 days ago

NOV18

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricte...

globenewswire.com•27 days ago

NOV17

CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and M...

prnewswire.com•28 days ago

NOV17

CYTK LAWSUIT ALERT: Levi & Korsinsky Notifies Cytokinetics, Incorporated Investors - Lead Plaintiff Deadline November 17, 2025

New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ: CYTK) investment and want to learn about a potential recovery under the fe...

newsfilecorp.com•28 days ago

NOV17

Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights – CYTK

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit...

globenewswire.com•28 days ago